|
1
|
Merchionne F, Perosa F and Dammacco F: New
therapies in multiple myeloma. Clin Exp Med. 7:83–97. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richardson PG, Barlogie B, Berenson J, et
al: A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hideshima T, Mitsiades C, Akiyama M, et
al: Molecular mechanisms mediating antimyeloma activity of
proteasome inhibitor PS-341. Blood. 101:1530–1534. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nencioni A, Grünebach F, Patrone F, et al:
Proteasome inhibitors: antitumor effects and beyond. Leukemia.
21:30–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Markovina S, Callander NS, O’Connor SL, et
al: Bortezomib-resistant nuclear factor-kappaB activity in multiple
myeloma cells. Mol Cancer Res. 6:1356–1364. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markovina S, Callander NS, O’Connor SL, et
al: Bone marrow stromal cells from multiple myeloma patients
uniquely induce bortezomib resistant NF-kappaB activity in myeloma
cells. Mol Cancer. 9:1762010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levine L: Proteasome inhibitors: their
effects on arachidonic acid release from cells in culture and
arachidonic acid metabolism in rat liver cells. BMC Pharmacol.
4:152004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rockwell P, Yuan H, Magnusson R and
Figueiredo-Pereira ME: Proteasome inhibition in neuronal cells
induces a proinflammatory response manifested by upregulation of
cyclooxygenase-2, its accumulation as ubiquitin conjugates, and
production of the prostaglandin PGE(2). Arch Biochem Biophys.
374:325–333. 2000. View Article : Google Scholar
|
|
9
|
Mbonye UR, Yuan C, Harris CE, et al: Two
distinct pathways for cyclooxygenase-2 protein degradation. J Biol
Chem. 283:8611–8623. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Voutsadakis IA, Patrikidou A, Tsapakidis
K, et al: Additive inhibition of colorectal cancer cell lines by
aspirin and bortezomib. Int J Colorectal Dis. 25:795–804. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu JF, Zhu GJ, Jamieson GG, et al: NS-398
induces apoptosis in human esophageal cancer cells through
inhibition of NF-kappaB downstream regulation of cyclooxygenase-2.
Cancer Invest. 27:17–23. 2009. View Article : Google Scholar
|
|
12
|
Jin ZJ: Addition in drug combination.
Zhongguo Yao Li Xue Bao. 1:70–76. 1980.(In Chinese).
|
|
13
|
Bae SH, Jung ES, Park YM, et al:
Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma
and growth inhibition of hepatoma cell lines by a COX-2 inhibitor,
NS-398. Clin Cancer Res. 7:1410–1418. 2001.PubMed/NCBI
|
|
14
|
Elder DJ, Halton DE, Crew TE and Paraskeva
C: Apoptosis induction and cyclooxygenase-2 regulation in human
colorectal adenoma and carcinoma cell lines by the
cyclooxygenase-2-selective non-steroidal anti-inflammatory drug
NS-398. Int J Cancer. 86:553–560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ladetto M, Vallet S, Trojan A, et al:
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple
myeloma and is an independent predictor of poor outcome. Blood.
105:4784–4791. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li QB, Chen ZC, You Y and Zou P: Small
interfering RNA of cyclooxygenase-2 induces growth inhibition and
apoptosis independently of Bcl-2 in human myeloma RPMI8226 cells.
Acta Pharmacol Sin. 28:1031–1036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ding J, Tsuboi K, Hoshikawa H, et al:
Cyclooxygenase isozymes are expressed in human myeloma cells but
not involved in anti-proliferative effect of cyclooxygenase
inhibitors. Mol Carcinog. 45:250–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang M, Abe Y, Matsushima T, et al:
Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in
myeloma cells via a Bcl-2 independent pathway. Leuk Lymphoma.
46:425–433. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Honjo S, Kase S, Osaki M, et al: COX-2
correlates with F-box protein, Skp2 expression and prognosis in
human gastric carcinoma. Int J Oncol. 26:353–360. 2005.PubMed/NCBI
|
|
20
|
Mizutani Y, Nakanishi H, Li YN, et al:
Enhanced sensitivity of bladder cancer cells to cisplatin mediated
cytotoxicity and apoptosis in vitro and in vivo by the selective
cyclooxygenase-2 inhibitor JTE-522. J Urol. 172:1474–1479. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin J, Hsiao PW, Chiu TH and Chao JI:
Combination of cyclooxygenase-2 inhibitors and oxaliplatin
increases the growth inhibition and death in human colon cancer
cells. Biochem Pharmacol. 70:658–667. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kishimoto Y, Yashima K, Morisawa T, et al:
Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc
expression in rat colon carcinogenesis induced by azoxymethane. J
Gastroenterol. 37:186–193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hideshima T, Ikeda H, Chauhan D, et al:
Bortezomib induces canonical nuclear factor-κB activation in
multiple myeloma cells. Blood. 114:1046–1052. 2009.
|
